OMass Therapeutics
PrivateLast Round
Series C
Oct 15, 2026
Est. Valuation
$468.8M
Total Funding Raised
$476.1M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
OMass Therapeutics is a biotechnology company that discovers and develops novel small molecule medicines for rare diseases and immunological conditions using its proprietary structural mass spectrometry technology platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OMass Therapeutics Comparables
Compare OMass Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Confo Therapeutics | 85% | |
| Ventus Therapeutics | 84% | |
| HotSpot Therapeutics | 84% |
OMass Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 15, 2026 | ||||
| Series B Extension | May 15, 2023 | ||||
| Series B | Apr 28, 2022 | ||||
| Series A Extension | Feb 17, 2020 | ||||
| Series A | Nov 21, 2018 |
OMass Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series C |
| Janus Henderson Group | Series C |
| SV Health Investors | Series C |
| GV | Series C, Series B Extension, Series B |
| Forbion | Series C |
| Syncona | Series B, Series C, Series B Extension, Series A Extension, Series A |
| Oxford Science Enterprises | Series A Extension, Series B, Series C, Series B Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 15, 2026
$310M round led by Novo Holdings, Bain Capital Life Sciences, and Forbion.
- Apr 28, 2026
Company faces lawsuit over intellectual property dispute.
Recent news
Latest coverage and updates
- identified_as_competitor_ofOct 18, 2026
OMass Technologies Ltd is a potential competitor to Vertex Pharmaceuticals LLC in congenital adrenal hyperplasia drugs as its $310 million financing advances a candidate, according to MedCity News.
- identified_as_competitor_ofOct 18, 2026
OMass Technologies Ltd seeks to compete with Neurocrine Biosciences, Inc. by advancing a congenital adrenal hyperplasia drug candidate after securing $310 million, MedCity News reports.
- recognized_asOct 15, 2026
Fierce Biotech names OMass Technologies Ltd a Fierce 15 winner in 2024 while the company remains preclinical.
- receives_financingOct 15, 2026
OMass Technologies Ltd receives an oversubscribed $310M Series C financing in United Kingdom on Oct 15th '26, co-led by Bain Capital Life Sciences, Forbion and Novo Holdings, to advance OMS1620 through Phase 2 development and generate early clinical data for an SLC15A4 inhibitor.
OMass Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about OMass Therapeutics's valuation, stock price, and market status.
Is OMass Therapeutics a public or private company?
OMass Therapeutics is a private company.
What is the current stock price of OMass Therapeutics?
OMass Therapeutics is a private company, so its shares have no public market price. Caplight tracks OMass Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is OMass Therapeutics worth (valuation)?
OMass Therapeutics's valuation is estimated at $468.8M based on funding round data.
Can I buy OMass Therapeutics stock?
OMass Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was OMass Therapeutics's last funding round?
OMass Therapeutics's most recent funding round was Series C on October 15, 2026.
Who are the main investors in OMass Therapeutics?
Key investors in OMass Therapeutics include Bain Capital Life Sciences, GV, Forbion, Syncona, Northpond Ventures.
Will OMass Therapeutics IPO soon?
No public IPO plans have been announced for OMass Therapeutics.
How can I track OMass Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in OMass Therapeutics's shares on secondary markets.